Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer

The mechanism by which trastuzumab‐emtansine (T‐DM1) causes systemic toxicities apart from trastuzumab alone is currently unknown. We hypothesized that the systemic toxicities from T‐DM1 may have been caused by the free and active maytansine released from the lysed HER2+ tumor cells, and if so, they...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Shou‐Ching, Capra, Carter L., Ajebo, Germame H., Meza‐Junco, Judith, Mairs, Simon, Craft, Barbara S., Zhu, Xiaofu, Maihle, Nita, Hillegass, William B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360077/
https://www.ncbi.nlm.nih.gov/pubmed/33844843
http://dx.doi.org/10.1002/ijc.33597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360077/
https://www.ncbi.nlm.nih.gov/pubmed/33844843
http://dx.doi.org/10.1002/ijc.33597

Ejemplares similares